In a major development for obesity treatment, global pharma powerhouse Eli Lilly and Company has secured approval from the US Food and Drug Administration for its new daily weight-loss pill, Foundayo (orforglipron), opening the door to a more accessible alternative to injectable therapies.
The drug is approved for adults with obesity—or those who are overweight with related medical conditions—and is designed to be taken once daily without food or water restrictions. The company says prescriptions are being accepted immediately, with shipments starting April 6 through LillyDirect, followed by wider rollout across U.S. pharmacies and telehealth platforms.
"People living with obesity need treatment options that meet them where they are – and for many, a once-daily pill that can be taken with no food or water restrictions can offer them greater flexibility in how they approach their treatment," said Deborah Horn, director of the Center for Obesity Medicine at McGovern Medical School at UTHealth Houston.
"With Foundayo, we now have an oral option that delivered an average of 12.4% weight loss at the highest dose in clinical trials – addressing both the clinical realities of obesity and the practical challenges patients face every day."
The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants. In its flagship trial, patients on the highest dose who completed treatment lost an average of 27.3 pounds (12.4%), compared to just 2.2 pounds (0.9%) on placebo. Even across all participants, regardless of completion, weight loss averaged 25 pounds (11.1%)—far exceeding placebo outcomes.
Beyond weight reduction, the drug also improved key cardiovascular risk markers, including cholesterol levels, blood pressure, and waist circumference.
"Today, fewer than 1 in 10 people who could benefit from a GLP-1 are taking one, held back by access, stigma, perceived complexity or the belief that their condition isn't serious enough for treatment. We believe Foundayo can help level the playing field for those living with obesity or who are overweight and living with weight-related complications," said David A Ricks, chair and CEO of Eli Lilly and Company.
"As a convenient, once-daily oral pill that delivers meaningful weight loss, this is obesity care designed for the real world."
Lilly is positioning Foundayo as a more affordable option in a market often criticized for high costs.
The company cautions that Foundayo should not be used alongside other GLP-1 drugs and has not been tested in children. It also carries warnings about potential thyroid tumors, including cancer, and lists common side effects such as nausea, diarrhea, and fatigue.
"There is no single path that works for everyone living with overweight or obesity," said Joe Nadglowski, president and CEO of the Obesity Action Coalition. "New treatment options expand choice and help more people find care that fits their lives, their goals and where they are in their journey – whether they're just starting to explore treatment or looking for a different long-term approach."
